1)In the core US market (70~80% portion), the key is expanding coverage based on increasing the number of co-occurring diseases (indications)
The efficacy and safety of injectable semaglutide 1.0 mg, a GLP-1 RA, were established by the SUSTAIN clinical trial programme in individuals with type 2 diabetes, along with real-world studies [9,10,11,12,13,14,15,16]
The information presented is about our medically supervised weight management programs and is not an advertisement for a specific drug
Another large study showed that using GLP-1s may help prevent immune-related diseases in people with diabetes or obesity People with diabetes who took GLP-1 drugs had a lower chance of developing rheumatoid arthritis, gout, and osteoarthritis compared to people on other diabetes medications
RFZO pokrie Kod dijabetesa tipa 2, deo terapije moe biti refundiran